"Insulet Corporation's victory against EOFlow highlights the significant risks involved when competitors hire former employees, revealing the vulnerability of trade secrets in the tech industry."
"Despite initial jury awards totaling $452M for misappropriated secrets, Insulet opted for a permanent injunction valued at $59.4M to secure its competitive advantage."
In a landmark decision, Insulet Corporation won a jury trial against EOFlow Co. for misappropriating trade secrets connected to the Omnipod insulin delivery system. The court awarded Insulet $452 million, later reduced to $59.4 million when Insulet chose a permanent injunction instead of a larger payout. Insulet's lawsuit was triggered by EOFlow's plans to launch a competing product called EOPatch, developed with the help of former Insulet employees. This case emphasizes the complexities and risks inherent in hiring talent from rival firms, particularly in technology-driven industries.
Read at Global IP & Technology Law Blog
Unable to calculate read time
Collection
[
|
...
]